Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim. It is being studied for obesity and metabolic dysfunction-associated steatohepatitis (MASH), with a focus on liver fat reduction.

In Phase 2 trials, Survodutide demonstrated up to 18.7% body weight reduction at 46 weeks. The glucagon receptor agonism may contribute to enhanced energy expenditure and liver fat reduction beyond what GLP-1 alone achieves.

Survodutide is administered as a weekly subcutaneous injection with dose escalation. Clinical trials have studied doses up to 4.8 mg weekly. The calculator helps determine injection volumes for research dosing.